Kellerhals Carrard advises GENE PREDICTIS on its sale to NIM

Kellerhals Karrard has advised the shareholders of GENE PREDICTIS, a Swiss-based medical diagnostic company and leader in the field of preventive health and precision medicine, in a sale transaction to NIMGenetics Genomica y Medicina (NIM), a leading Spanish biotech company in the field of human genetic diagnostics and a portfolio company of Apposite Capital.

Since its foundation in 2004, Gene Predictis has created a unique expertise in developing polygenic and multifactorial risk scores for interpreting complex genetic data.

This acquisition reinforces NIM’s firm intent to its international expansion, with a focus on Central
European markets, and bring additional verticals such as pharmacogenetics, microbiology, and
infectious diseases.

The Kellerhals Carrard team comprised Frédéric Rochat (partner, pictured left) and Anne-Gabrielle Piaget (counsel, pictured right). Advice and support to NIM was provided by BDO, Pinsent and BAT Law.